WEKO3
アイテム
{"_buckets": {"deposit": "1cfe8c8b-c96c-4bc1-b470-7c376cfcb89b"}, "_deposit": {"created_by": 1, "id": "71732", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "71732"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00071732", "sets": ["28"]}, "author_link": ["705949", "705942", "705943", "705938", "705947", "705953", "705956", "705944", "705946", "705955", "705957", "705958", "705951", "705959", "705940", "705952", "705945", "705948", "705950", "705941", "705954", "705939"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2015-05-28", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: The indole-containing small molecule 1-methyl-tryptophan (1MTrp) is known as a specific inhibitor targeted immune checkpoint protein indoleamine-2,3-dioxygenase (IDO)- switching off the effector T cells of the immune system to support tumor growth. 1MTrp has shown attractive antitumor activity without noticeable toxicity [1], and its phase I trial had been completed in 2014. However, 1MTrp exists as 2 stereoisomers of L and D. Most preclinical studies have employed the racemic mixture, thus leaving a long-standing debate in immunology and oncology, which stereoisomers have the potential of immune checkpoint inhibitor [2,3]. To remove the blindfold of 1MTrp effects and guide its immunotherapy development, we synthesized 1-N-[11C]methyl]-L- and -D-tryptophan ([11C]L-1MTrp and [11C]D-1-MTrp) and compared their pharmacokinetics by PET.\nMethods: [11C]L-1MTrp and [11C]D-1MTrp were synthesized by reaction of the corresponding Boc-Trp-OEt with [11C]CH3I at 80 °C for 5 min, followed by deprotection with 2 N HCl at 100 °C for 5 min. Pharmacokinetics of the L and D isomers were compared by dynamic PET scans and biodistribution study following the injection of the radioprobes in rats. \nResults: [11C]L-1MTrp and [11C]D-1MTrp were obtained with radiochemical yields of 47.0 ± 6.3% (n = 80, based on [11C]CO2, EOS), radiochemical purity of \u003e 98%, and specific activity of 47―130 GBq/μmol, showing high enantiomeric purity. PET imaging in rats revealed [11C]L-1MTrp had the highest accumulation of radioactivity (SUV 2.88 ± 0.03) in the pancreas with high IDO expression, while [11C]D-1MTrp showed the highest uptake (SUV 1.16 ± 0.03) in the kidney at 60 min after the radioprobes injection respectively. Ex vivo biodistribution results supported the PET images and indicated that uptake of L isomer in each organ was significantly higher than D isomer except in the kidney. Quite different tissue distribution was verified between the 2 stereoisomers. \nConclusions: Both [11C]L-1MTrp and [11C]D-1MTrp are useful PET probes for tracking the pharmacokinetics of 1MT in vivo. Imaging the immune checkpoint inhibitors would enable us to take a new look at cancer immunotherapy and drug development.\n\\nReference: [1].Muller AJ, et al. Nat Med. 2005;11:312. [2]. Hou DY, et al. Cancer Res. 2007;67:792. [3] Lob S, et al. Blood. 2008;111:2152.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "21st International Symposium on Radiopharmaceutical Sciences", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kumata, Katsushi"}], "nameIdentifiers": [{"nameIdentifier": "705938", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xie, Lin"}], "nameIdentifiers": [{"nameIdentifier": "705939", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yui, Joji"}], "nameIdentifiers": [{"nameIdentifier": "705940", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hatori, Akiko"}], "nameIdentifiers": [{"nameIdentifier": "705941", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding"}], "nameIdentifiers": [{"nameIdentifier": "705942", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nengaki, Nobuki"}], "nameIdentifiers": [{"nameIdentifier": "705943", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujinaga, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "705944", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamasaki, Tomoteru"}], "nameIdentifiers": [{"nameIdentifier": "705945", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimoda, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "705946", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maeda, Jun"}], "nameIdentifiers": [{"nameIdentifier": "705947", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "705948", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "熊田 勝志", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705949", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "謝 琳", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705950", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "由井 譲二", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705951", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "羽鳥 晶子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705952", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 一鼎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705953", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "念垣 信樹", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705954", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "藤永 雅之", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705955", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山崎 友照", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705956", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "下田 陽子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705957", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "前田 純", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705958", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 明栄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "705959", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Radiosynthesis and pharmacokinetic comparison of 1-N-[11C]methyl]-L- and -D-tryptophan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Radiosynthesis and pharmacokinetic comparison of 1-N-[11C]methyl]-L- and -D-tryptophan"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/71732", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-06-18"}, "publish_date": "2015-06-18", "publish_status": "0", "recid": "71732", "relation": {}, "relation_version_is_last": true, "title": ["Radiosynthesis and pharmacokinetic comparison of 1-N-[11C]methyl]-L- and -D-tryptophan"], "weko_shared_id": -1}
Radiosynthesis and pharmacokinetic comparison of 1-N-[11C]methyl]-L- and -D-tryptophan
https://repo.qst.go.jp/records/71732
https://repo.qst.go.jp/records/71732b4fc7742-cbae-4426-9c41-e2f5275e113a
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-06-18 | |||||
タイトル | ||||||
タイトル | Radiosynthesis and pharmacokinetic comparison of 1-N-[11C]methyl]-L- and -D-tryptophan | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kumata, Katsushi
× Kumata, Katsushi× Xie, Lin× Yui, Joji× Hatori, Akiko× Zhang, Yiding× Nengaki, Nobuki× Fujinaga, Masayuki× Yamasaki, Tomoteru× Shimoda, Yoko× Maeda, Jun× Zhang, Ming-Rong× 熊田 勝志× 謝 琳× 由井 譲二× 羽鳥 晶子× 張 一鼎× 念垣 信樹× 藤永 雅之× 山崎 友照× 下田 陽子× 前田 純× 張 明栄 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: The indole-containing small molecule 1-methyl-tryptophan (1MTrp) is known as a specific inhibitor targeted immune checkpoint protein indoleamine-2,3-dioxygenase (IDO)- switching off the effector T cells of the immune system to support tumor growth. 1MTrp has shown attractive antitumor activity without noticeable toxicity [1], and its phase I trial had been completed in 2014. However, 1MTrp exists as 2 stereoisomers of L and D. Most preclinical studies have employed the racemic mixture, thus leaving a long-standing debate in immunology and oncology, which stereoisomers have the potential of immune checkpoint inhibitor [2,3]. To remove the blindfold of 1MTrp effects and guide its immunotherapy development, we synthesized 1-N-[11C]methyl]-L- and -D-tryptophan ([11C]L-1MTrp and [11C]D-1-MTrp) and compared their pharmacokinetics by PET. Methods: [11C]L-1MTrp and [11C]D-1MTrp were synthesized by reaction of the corresponding Boc-Trp-OEt with [11C]CH3I at 80 °C for 5 min, followed by deprotection with 2 N HCl at 100 °C for 5 min. Pharmacokinetics of the L and D isomers were compared by dynamic PET scans and biodistribution study following the injection of the radioprobes in rats. Results: [11C]L-1MTrp and [11C]D-1MTrp were obtained with radiochemical yields of 47.0 ± 6.3% (n = 80, based on [11C]CO2, EOS), radiochemical purity of > 98%, and specific activity of 47―130 GBq/μmol, showing high enantiomeric purity. PET imaging in rats revealed [11C]L-1MTrp had the highest accumulation of radioactivity (SUV 2.88 ± 0.03) in the pancreas with high IDO expression, while [11C]D-1MTrp showed the highest uptake (SUV 1.16 ± 0.03) in the kidney at 60 min after the radioprobes injection respectively. Ex vivo biodistribution results supported the PET images and indicated that uptake of L isomer in each organ was significantly higher than D isomer except in the kidney. Quite different tissue distribution was verified between the 2 stereoisomers. Conclusions: Both [11C]L-1MTrp and [11C]D-1MTrp are useful PET probes for tracking the pharmacokinetics of 1MT in vivo. Imaging the immune checkpoint inhibitors would enable us to take a new look at cancer immunotherapy and drug development. \nReference: [1].Muller AJ, et al. Nat Med. 2005;11:312. [2]. Hou DY, et al. Cancer Res. 2007;67:792. [3] Lob S, et al. Blood. 2008;111:2152. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 21st International Symposium on Radiopharmaceutical Sciences | |||||
発表年月日 | ||||||
日付 | 2015-05-28 | |||||
日付タイプ | Issued |